OUR PEOPLE

Management Team

Michael T. Redman, CEO & Board Member

Mr. Redman is the chief executive officer of Oncolix, Inc. and has served in this position since formation of the company in November of 2006.

Prior to Oncolix, Mr. Redman was the CEO of Bone Medical, a public company focused in the area of oral peptide delivery of products related to musculoskeletal disorders. Immediately prior to Bone Medical, Mr. Redman was the CEO and co-founder of Opexa Pharmaceuticals, which commenced operations in February of 2001 and was successfully sold to PharmaFrontiers Corporation in November of 2004. PharmaFrontiers later reorganized the company, which is now named Opexa Therapeutics, a NASDAQ-listed company.

His career spans over 25 years in the pharmaceuticals and biotechnology industry and encompasses leadership in sales, marketing, business and commercial development. In addition to the three companies in which he served as CEO, Mr. Redman also held key management positions with Zonagen, Aronex Pharmaceuticals, Biovail, and American Home Products.

Mr. Redman has been instrumental in closing multiple pharmaceutical licensing deals, both domestic and international. These deals include in-licensing of university and NIH intellectual property, acquisitions and divestitures. He is an active member of the Licensing Executives Society and formerly served on its Executive Committee. Mr. Redman earned a BA in Biology from the University of Missouri and a Masters in Business Administration from the University of Phoenix.

Wen Y. Chen, Ph.D. Inventor
Dr. Chen is the primary inventor of Prolanta™ and a full-professor at Clemson University in South Carolina. He is an internationally-recognized molecular endocrinologist who has made significant contributions to the development of a growth hormone antagonist for the treatment of acromegaly, Somavert^®.

During the past decade, Dr. Chen has focused his research on the role of prolactin in breast cancer. He has published more than 50 scientific papers and holds multiple patents. Dr. Chen currently leads studies to develop prolactin antagonists specifically designed for breast cancer. His work includes the potential use of human prolactin analogues as a mammary gland differentiation factor, which may open a new avenue for the use of hPRL antagonists/agonists as chemo-preventative agents.

Dr. Chen has been awarded five grants relating to prolactin research from agencies and organizations including The Department of Defense, US Army Research Command, the NIH/NCI and the Susan G. Komen Foundation. He has authored one US patent relating to prolactin and an additional five related US patents are pending.

Mitzi Martinez-Montgomery, D.V.M., Ph.D. VP of Scientific Affairs

Dr. Montgomery serves as the Vice President of Scientific Affairs. She is responsible for preclinical development, regulatory affairs, technology optimization and technology transfer.

Prior to joining Oncolix, Dr. Montgomery served in a number of capacities with Opexa Therapeutics, including VP of Discovery & Preclinical Development and VP of Development. At Opexa, she was responsible for technology transfer and optimization of an autologous T cell vaccine for multiple sclerosis, including formulation, stability and manufacturing cost reductions. She also served as the project manager directing clinical research activities and managing contract research organizations involved in human clinical trials for the autologous T cell vaccine. Dr. Montgomery managed the optimization of the vaccine and was largely responsible for taking the drug to Phase IIb clinical trials. She also managed the production and research staff of the company.

Dr. Montgomery has a Ph.D. in Immunology and a DVM with over sixteen years experience in the biotechnology industry and over fourteen years experience in laboratory animal medicine and preclinical testing (small animals and primates). Dr. Montgomery served as the Director of Preclinical Development and was the former manager of a full GLP-compliant toxicology lab at Zonagen, Inc. She has the expertise to manage the activities necessary for all IND requirements in addition to the leadership responsibilities to manage ongoing research and development through to clinical trials. Dr. Montgomery also gained postdoctoral experience in vaccine development at SmithKline Beecham and was a practicing veterinarian for eight years. She received her Ph.D. from Auburn University in 1992, a D.V.M from the University of Tennessee in 1981, and a BA from Vanderbilt in 1976.